Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With T. Pedis
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
This is an open- label, single- dose, dose escalating evaluation of the safety and
tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
The purpose of the current protocol is to establish the safety and tolerability of a single
application of J. lividum to the feet of patients with proven T. pedis. In addition, the
effect of J liv on the T. pedis will also be evaluated.